SCHEMBL6798355

SCHEMBL6798355

O=C(O)c1cccnc1C=Cc1ccc2ccccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RELA Q04206 1/20 0.50
CYP3A4 P08684 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP1A1 P04798 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP1B1 Q16678 1/20 0.47
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
HSP90AA1 P07900 1/20 0.46
PTGS1 P23219 1/20 0.45
PTPN1 P18031 1/20 0.43
HNF4A P41235 1/20 0.43
LMNA P02545 2/20 0.43
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HPGD P15428 1/20 0.43
PPARA Q07869 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1905601 0.84 KDM4E (0.52) CYP3A4CYP1A2ALDH1A1SMN1; SMN2NPC1
SCHEMBL1905604 0.84 KDM4E (0.52) CYP3A4CYP1A2ALDH1A1SMN1; SMN2NPC1
Hydrochloric Acid SCHEMBL6800822 0.80 TSHR (0.44) CYP3A4CYP1A2CYP1A1CYP2D6CYP1B1
SCHEMBL9000477 0.80 KDM4E (0.55) CYP3A4ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL4684421 0.80 RELA (0.46) RELACYP3A4CYP1A2CYP1A1CYP2D6
SCHEMBL10414536 0.78 FGF23 (0.56) CYP3A4ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL6386356 0.78 NAPRT (0.51) CYP3A4ALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL10414535 0.78 FGF23 (0.56) CYP3A4ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL6386359 0.78 NAPRT (0.51) CYP3A4ALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL7322163 0.78 GRIK1 (0.59) RELACYP3A4CYP1A2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040097508-A1 Novel heterocyclically substituted amides, their preparation and use ABBOTT GMBH & CO. KG (DE) 2004-05-20 US disclosed
US-6630493-B1 Inhibitors of capain enzymes useful for the treatment of ischemias of the heart, the kidney or of central nervous system (e.g. \"stroke\"), inflammations, muscular dystrophy, cataracts of the eyes, Alzheimer's disease etc. BASF AKTIENGESELLSCHAFT (DE) 2003-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097508-A1 Novel heterocyclically substituted amides, their preparation and use CAPN1, CAPNS1, CAPN2 RELA 3648/4885CYP3A4 1904/4885CYP1A2 2635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.